NDA 207997 · Novartis
Rydapt
Midostaurin · Oral · Kinase Inhibitor
NovelPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: May 22, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Apr 28, 2017
Approved uses
3
Original approval plus efficacy supplements
Registered trials
53
11 Phase 3, 4 recruiting
FAERS reports
1,957
1,424 serious, 472 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 8, 2026.
RYDAPT is a kinase inhibitor indicated for the treatment of adult patients with: Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. ( 1.1 ) Limitations of Use: RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML. Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL). ( 1.2 ) 1.1 Acute Myeloid Leukemia RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive, as detected by an FDA approved test [see Dosage and Administration (2.1), Clinical Studies (14.1)]. Limitations of Use RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML. 1.2 Systemic Mastocytosis RYDAPT is indicated for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).
Mechanism: Midostaurin is a small molecule that inhibits multiple receptor tyrosine kinases. In vitro biochemical or cellular assays have shown that midostaurin or its major human active metabolites CGP62221 and CGP52421 inhibit the activity of wild type FLT3, FLT3 mutant kinases (ITD and TKD), KIT (wild type and D816V mutant), PDGFRα/β, as well as members of the serine/threonine kinase PKC (protein kinase C) family. Midostaurin demonstrated the ability to inhibit FLT3 receptor signaling and cell proliferation, and it induced apoptosis in leukemic cells expressing ITD and TKD mutant FLT3 receptors or...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 24, 2020 Supplement 6 · Efficacy · priority review OrphanLabelLetter
- Apr 28, 2017 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
- Apr 28, 2017 Original approval · Efficacy · priority review NovelOrphanLabelLetter
1 products under this application
- RYDAPT · MIDOSTAURIN 25MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Midostaurin" as an intervention, any sponsor and status, largest first.
- Prospective Evaluation of Response to Treatment in Younger Adult Patients (18-60 Years) With Acute Myeloid Leukemia (AML)Pivotal-lookingNot yet recruiting
University Hospital, ToulouseAcademic, hospital or other
NCT07948122 · 1,290 participants (planned) · Start Jan 4, 2027 · Primary completion Dec 31, 2035
Drug: Quizartinib; Midostaurin and 2 more · For: Acute Myeloid Leukemia
Sites: Amiens, France; Angers, France; Argenteuil, France · 55 sites in all
- A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive ChemotherapyPivotal-lookingActive, not recruiting
Stichting Hemato-Oncologie voor Volwassenen NederlandAcademic, hospital or other
NCT04027309 · 777 participants · Start Dec 20, 2019 · Primary completion Oct 2025
Drug: Gilteritinib; Midostaurin · For: Acute Myeloid Leukemia; Myelodysplastic Syndrome With Excess Blasts-2
Sites: Adelaide, Australia; Brisbane, Australia; Camperdown, Australia · 193 sites in all
- Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaPivotal-lookingCompleted
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT00651261 · 717 participants · Start Apr 2008 · Primary completion Jul 2016
Drug: cytarabine; daunorubicin and 2 more · For: Leukemia
Sites: Birmingham, Alabama; Little Rock, Arkansas; Sacramento, California · 176 sites in all
- A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03512197 · 511 participants · Start Jul 20, 2018 · Primary completion Feb 12, 2021
Drug: Midostaurin; Placebo and 1 more · For: Acute Myeloid Leukemia (AML)
Sites: Chicago, Illinois; Boston, Massachusetts; Portland, Oregon · 133 sites in all
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT02115295 · 508 participants (planned) · Start May 19, 2014 · Primary completion May 31, 2030
Drug: Cladribine; Cytarabine and 4 more · For: Acute Biphenotypic Leukemia; Acute Myeloid Leukemia; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and 11 more
Sites: Houston, Texas
University of UlmAcademic, hospital or other
NCT01477606 · 451 participants · Start May 2012 · Primary completion Feb 26, 2020
Drug: Midostaurin; Cytarabine and 1 more · For: Acute Myeloid Leukemia
Sites: Innsbruck, Austria; Linz, Austria; Salzburg, Austria · 55 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT03379727 · 301 participants · Start Feb 13, 2018 · Primary completion Jul 9, 2021
Drug: Midostaurin; Cytarabine and 1 more · For: Acute Myeloid Leukemia
Sites: Pleven, Bulgaria; Sofia, Bulgaria; Varna, Bulgaria · 86 sites in all
- FLT3-ITD Targeted Therapy in Fit AML PatientsPivotal-lookingNot yet recruiting
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT07425808 · 230 participants (planned) · Start Dec 1, 2026 · Primary completion Oct 1, 2028
Drug: Gilteritinib; Venetoclax and 2 more · For: AML (Acute Myeloid Leukemia)
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death329
- nausea166
- vomiting105
- drug ineffective100
- acute myeloid leukaemia recurrent93
- pancytopenia93
- pyrexia91
- diarrhoea90
- febrile neutropenia78
- bone marrow failure76
- drug intolerance73
- lymphadenopathy60
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 182 |
| 2018 | 299 |
| 2019 | 342 |
| 2020 | 365 |
| 2021 | 280 |
| 2022 | 160 |
| 2023 | 148 |
| 2024 | 84 |
| 2025 | 37 |
| 2026 | 60 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Rydapt (Midostaurin)
2024 spending
$27.4M
Beneficiaries
330
1,389 claims
Per beneficiary
$83,116
$191.35 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $37,074,047 |
| 2021 | $35,250,983 |
| 2022 | $30,083,178 |
| 2023 | $30,688,892 |
| 2024 | $27,428,239 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
Stone RM, Mandrekar SJ, Sanford BL, et al. · N Engl J Med 2017 · Clinical Trial, Phase III, Multicenter Study
- Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association.
Stemler J, de Jonge N, Skoetz N, et al. · Lancet Haematol 2022 · Systematic Review, Consensus Statement
- Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML.
Russell N, Othman J, Cumming O, et al. · Blood Adv 2025 · Randomized Controlled Trial
- Midostaurin in Advanced Systemic Mastocytosis.
Chandesris MO, Damaj G, Canioni D, et al. · N Engl J Med 2016 · Controlled Clinical Trial, Letter
- Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia.
Solana-Altabella A, Ballesta-López O, Megías-Vericat JE, et al. · Expert Opin Emerg Drugs 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.
Kadia TM, Reville PK, Borthakur G, et al. · Lancet Haematol 2021 · Clinical Trial, Phase II
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.